Chinese biotechnology company BeiGene Ltd and Guangzhou Development District (GDD) have formed a joint venture, BeiGene Biologics Co Ltd, that will invest RMB 2.2 billion ($ 330 million) to build a biologics manufacturing facility in Guangzhou, Guangdong Province, China. The joint venture will also provide funding for research and development of biologic drug candidates in China.
“We are very pleased to announce our joint venture with the Guangzhou Development District. Biologics represent an important part of BeiGene’s overall R&D and manufacturing capabilities. This joint venture will enable BeiGene to keep pace with a growing demand for the development and use of